Phase 1 Type 2 Diabetes Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with non-small cell lung cancer (NSCLC) confirmed by a tissue sample, and your cancer can be measured on scans (some groups in the trial do not require measurable disease — confirm with trial site)
• Your cancer is at an advanced stage that cannot be removed by surgery (Stage III or Stage IV), although some groups in the trial have different stage requirements depending on which part of the trial you may join (confirm with trial site)
• You are generally well enough to carry out some daily activities, as measured by a standard scale used by doctors (called ECOG performance status 0–1, or 0–2 depending on which group in the trial you may join — confirm with trial site)
• Depending on which group in the trial you may qualify for, you may need to have already received certain previous treatments, such as immunotherapy (a type of drug that helps your immune system fight cancer) and/or platinum-based chemotherapy
• For some groups, your cancer must show certain levels of a protein called PD-L1 on the tumor cells, as tested by a local lab (confirm with trial site)
• For some groups, your cancer must have specific gene changes (such as EGFR, ALK, or RET mutations), and you must currently be receiving a standard targeted treatment for those gene changes (these groups are only available at selected US sites — confirm with trial site)
• For some groups, you must have previously had a combined treatment of chemotherapy and radiation (chemoradiotherapy) for cancer that could not be removed by surgery
• For one group, your cancer must be considered suitable for surgical removal and for treatment given before surgery (called neoadjuvant treatment)
• For some groups, you must be able to tolerate a type of immunotherapy drug called an anti-PD-1 therapy, meaning you have not had to permanently stop this type of treatment in the past due to serious side effects

Who may not be able to join:

• You are currently receiving active cancer treatment for your NSCLC (some exceptions may apply depending on your group — confirm with trial site)
• Your cancer has a specific gene mutation for which an approved targeted treatment exists, and you are a suitable candidate for that treatment (exceptions exist for the EGFR and ALK/RET groups — confirm with trial site)
• You have had a significant autoimmune disease (where the immune system attacks the body) in the last 5 years that required strong immune-suppressing medication (some milder autoimmune conditions, such as stable thyroid problems, vitiligo, or psoriasis, may still be eligible — confirm with trial site)
• Your brain or spinal cancer has been growing or is newly detected during the screening period, or you have cancer spread to the lining around the brain or spinal cord (some exceptions may apply if the brain or spinal spread has been treated and is stable — confirm with trial site)
• You are currently taking high-dose steroid medication on a long-term basis (a low dose of up to 5 mg per day of prednisolone or equivalent may be acceptable — confirm with trial site)
• You have received other treatments that significantly suppress your immune system within the last 3 months
• You are living with HIV with a very low level of certain immune cells (CD4+ count below 350) and have a history of serious HIV-related infections
• You have had your spleen removed
• You have a history of, or are at risk of, a serious lung condition called interstitial lung disease, or your blood oxygen level at rest is below 92% without additional oxygen support

Important: Always verify eligibility with the trial site directly before applying.